Lung Cancer Prognosis Market likely to witness an impressive Healthy CAGR by 2025, as estimated by Stratview Research

Stratview Research in its recent report has offered an overlook of the current Lung Cancer Prognosis Market scenarios and has also estimated the Lung Cancer Prognosis Market size to reach grow at Healthy CAGR by 2025. The insights highlighted in the report are based on data that is carefully collected from reliable sources and is then scrutinized to have a proper analysis.
Not only the report offers the market size but also details about the market segmentation with its share. Stratview Research also extends its research to offer a forecast of the market during the period of 2018 – 2025, to provide the clients with base knowledge of the market and make strategies to have beneficial results ahead.

Click here for a Free Sample of the report (additional insights inside):
https://www.stratviewresearch.com/Request-Sample/425/lung-cancer-prognosis-market.html

In the Lung Cancer Diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision making process is equally high among the Lung Cancer Management Market. The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.

Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.29%, over the course of forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%. In some cases surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus – the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.31% over the course of seven years. The study on the Lung Cancer Management Market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence it is the highly referred type of surgery procedure for NSCLC cases. One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.

Among the different segments of Global Lung Cancer Management Market, connected health or Apps for Lung cancer maintenance or management are few. However, the segment is promising, as researchers believe that App based software can help in treatment adherence, keeping track of medical records (insurance companies, medical centres). Developed markets such as USA, UK, Germany, France, Japan, China and Australia are the near term opportunities.

Lung cancer patients need nutritional supplements throughout their treatment phase followed by recovery and maintenance phase. The study from Stratview Research also looks at the aspects of sales and marketing, buying patterns of end users which can help companies such as Abbott, Danone, Nestle, B Braun and more gauge the market and look at the changing preferences of the market in regions such as Asia Pacific, Europe and North America.

Finally the report on Lung Cancer Prognosis also focuses on the regional aspects and gives the reader the flexibility to consider between global market as whole or regions in particular. It is imperative to look at this market as connected as out of the prevalent cases of Lung cancer are potential candidates of diagnosis and of the diagnosed pool a higher percentage will require medication or surgery, there will be few drop outs and few gaps, more or less all the above will need apps or Healthcare IT products to monitor drug adherence, doctor access, and above all long term nutritional supplement.

Hence, readers may consider this inter-linked market under the Lung cancer management market and consider the opportunities that exist in each segment from 2019-2025.

Click here for description of the report:
https://www.stratviewresearch.com/425/lung-cancer-prognosis-market.html

Highlights of the Report:
For the first time in market, one report exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters. Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.

If we consider the Lung Cancer Management Market from the stakeholder’s perspective, then drugs approved for Small Cell Lung Cancer will not be applicable for Non-Small Cell Lung Cancer. What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away? Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors? Who all are the active players and who are newbies. Will the differential cost of therapeutics across the regions impact the drug sales in North America versus APAC? In the Small Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow a CAGR of 7.44% globally however the same class of drugs might grow at a CAGR of 10.59% in the Non-Small Scale Lung Cancer Therapeutics Market in the same time period.

Considering that all the drugs mentioned above have a bright future till 2025, how many companies would like to compete in this market. How will the new joiners react if they consider that the market had a potential of USD 17.11 Billion alone in 2018 and is likely to grow at a CAGR of 8.28% globally till 2025.

Check out the Table of Contents here:
https://www.stratviewresearch.com/toc/425/lung-cancer-prognosis-market.html

Features of the Report
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools.

The Lung Cancer Prognosis Market analysis report discusses the following heads in great detail:
• Market structure: Overview, industry life cycle analysis, supply chain analysis
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
• Market trend and forecast analysis
• Market segment trend and forecast
• Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
• Attractive market segments and associated growth opportunities
• Emerging trends
• Strategic growth opportunities for the existing and new players
• Key success factors

Stratview Research
400 Renaissance Center,
Suite 2600,
Detroit, Michigan, MI 48243
United States of America
Phone No. +1-313-307-4176
sales@stratviewresearch.com

Know more about us and our reports:
Stratview Research has been offering its insightful reports and custom researches to the interested clients in some of important industry sectors such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas. The data is collected for the reports is collected from reliable sources and is analysed carefully to come up with an end result that is resourceful and worthy for the interesting clients.

This release was published on openPR.